ESPE European Society for Paediatric Endocrinology
Hear from those who are helping shape the ESPE 2020 experience! Find out more at: www.eurospe.org/meetings/2020/espe2020/ and see why you need to attend this year’s Meeting in Liverpool from the 10 – 12 September 2020.
Share this Video
Related Videos In Paediatric Endocrinology
Bradley Miller, ESPE 2022: Advantages of Somapacitan versus Daily GH in Children with GH Deficiency
Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the challenges of GH therapy in children and the […]
Bradley Miller, ESPE 2022: Once-Weekly Somapacitan versus Daily GH in Children with GH Deficiency: The REAL 4 Trial
The REAL 4 trial is a multicenter, randomized, controlled, double-blind phase 3 study (NCT03811535) to evaluate the efficacy, safety, and tolerability of once-weekly somapacitan vs once-daily growth hormone (GH). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the aims, design and results of the REAL 4 trial. The next […]
Uberto Pagotto, ESPE 2022: GLP-1 Agonists and Other Emerging Treatments of Obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!